Inhaled Insulin Treatment
EDM number 2019 in 2005-06, proposed by Mike Penning on 24/04/2006.
That this House expresses its deep concern that the National Institute for Health and Clinical Excellence (NICE) appraisal consultation document (ACD) recommends that new inhaled insulin should not be available to NHS patients with diabetes although diabetes is a major and growing health problem that affects two million people in the UK, and complications arising from poor management of the condition costs the NHS £5 billion every year; notes that both the Food and Drug Administration and the European Medicines Evaluation Agency granted inhaled insulin a licence based on robust scientific and medical evidence and that it is one of the most significant medical breakthroughs in diabetes treatment since the discovery of insulin in the 1920s; regrets that the UK had the opportunity to be at the forefront of this development in improving diabetic care, and that the NICE ACD means that patients with diabetes in the UK will either have to pay for this new mode of treatment or continue with the daily multiple injections that lie at the heart of so many problems in managing the disease; and calls upon the Government to find ways to ensure that the NHS provides early and free access to inhaled insulin, so that the benefits of this new approach can be realised for patients in the UK.
This motion has been signed by a total of 83 MPs.
Download raw data as csv or xml.